Inozyme Pharma, Inc. (INZY) Dividend History

Inozyme Pharma, Inc. (INZY) is a biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic diseases caused by abnormal mineralization. The company's research centers on enzymes and related treatments to address conditions such as calcification disorders, aiming to improve patient outcomes through innovative molecular approaches.

321 Summer Street, Boston, MA, 02210
Phone: 857-330-4340
Website: https://www.inozyme.com

Dividend History

Inozyme Pharma, Inc. currently does not pay dividends

Company News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders

Halper Sadeh LLC is investigating several companies, including SpringWorks Therapeutics, NV5 Global, Charter Communications, and Inozyme Pharma, for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.

GlobeNewswire Inc.

Featured Companies: CHTR NVEE SWTX
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency

GlobeNewswire Inc.
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented

GlobeNewswire Inc.
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company will present recently announced topline data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (manifesting as pseudoxanthoma elasticum, or PXE), during oral presentations at two upcoming medical conferences.

GlobeNewswire Inc.
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 01:22:15 UTC